Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
4basebio PLC - Cambridge, England-based life sciences company and manufacturer of synthetic DNA products - Names Gabe Longoria as the new chief commercial officer. Longoria was previously CCO at Astrea Bioseparations Ltd. The appointment follows a £40 million investment into 4basebio by Elevate Medical Technologies and M&G Investment Management Ltd, which completed in November. This is a ‘key milestone’ for the company.
Chief Executive Officer Heikki Lanckriet says: ‘As we focus on capitalising on our recent £40 million investment, Gabe’s leadership will be invaluable in accelerating our efforts to bring our synthetic DNA products to market and deliver value to our customers and stakeholders.’
Current stock price: 1,208.00 pence
12-month change: up 73%
Copyright 2025 Alliance News Ltd. All Rights Reserved.